Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

LH - Labcorp Holdings Inc. So'nggi Yangiliklar | Finranks

Home

LH

L

Labcorp Holdings Inc. (LH)

NYQ – Real vaqt narxi. Valyuta: USD

264.20

-4.18 (-1.56%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

264.73

+0.53 (0.20%)

Bozordan keyin: Mar 27, 2026, 6:19 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term

Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Is Labcorp (LH) Down 4.6% Since Last Earnings Report?

Why Is Labcorp (LH) Down 4.6% Since Last Earnings Report?

Labcorp (LH) reported earnings 30 days ago. What's next for the stock?

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

Labcorp Holdings (LH) is a Top-Ranked Value Stock: Should You Buy?

Labcorp Holdings (LH) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Is This the Right Time to Hold Labcorp Stock in Your Portfolio?

Is This the Right Time to Hold Labcorp Stock in Your Portfolio?

LH eyes growth via specialty test expansion, acquisitions and LaunchPad savings, but currency headwinds and macro pressures cloud the outlook.

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patient care BURLINGTON, N.C., Feb. 23, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations.

Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term

Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Videolar

No Data

There is no data to display

Press-relizlar

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patient care BURLINGTON, N.C., Feb. 23, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations.

Labcorp Announces 2025 Fourth Quarter and Full Year Results

Labcorp Announces 2025 Fourth Quarter and Full Year Results

Company Provides 2026 Guidance Financial results from Operations versus 2024: Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs $13.01 billion Diluted EPS: Q4 of $1.98 vs $1.70; Full year of $10.46 vs $8.84 Adjusted EPS: Q4 of $4.07 vs $3.45; Full year of $16.44 vs $14.57 Free Cash Flow: Q4 of $490.3 million vs. $665.1 million; Full year of $1.21 billion vs $1.10 billion Provided Full-Year 2026 Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4% Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9% Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8% Expanded partnerships with health systems and regional/local laboratories by signing or closing 13 transactions in 2025 Advanced leadership in specialty testing, launching more than 130 innovative new tests in 2025, including in oncology, women's health, neurology and autoimmune Announced strategic investment to build a modern, state-of-the-art 500,000 square foot Central Laboratory facility to address growth in demand BURLINGTON, N.C.

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

Elecsys ® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathology Now available nationwide in primary care settings for patients aged 55 and older experiencing symptoms of cognitive decline Expands Labcorp's comprehensive portfolio of Alzheimer's disease blood tests across both primary and specialty care settings BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment of Alzheimer's disease in the primary care setting.